Search Within

Jonathan T Hersch

Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (6)
  2. Gastrointestinal Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Center for Pancreatic Cancer Research (5)
  5. Survivorship Research (3)
  6. Biostatistics Service (2)

More Groups

People
  1. Anna Varghese (3)
  2. Leonard Saltz (3)
  3. Rona Yaeger (3)
  4. David Bates (2)
  5. David Kelsen (2)
  6. Joanne Chou (2)

More People

Years
  1. 2020 (2)
  2. 2018 (4)
Publications
  1. Journal of Clinical Oncology (2)
  2. Cancer Research (1)
  3. Clinical Cancer Research (1)
  4. Clinical Colorectal Cancer (1)
  5. JCO Precision Oncology (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. American Association for Cancer Research (2)
  3. Elsevier Inc. (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Systemic chemotherapy for metastatic colitis-associated cancer has a worse outcome than sporadic colorectal cancer: Matched case cohort analysis
    Journal Article

    Yaeger, R.; Paroder, V.; Bates, D. D. B.; Capanu, M.; Chou, J.; Tang, L.; Chatila, W.; Schultz, N.; Hersch, J.; Kelsen, D.
    Clinical Colorectal Cancer (2020)

    Fulltext@MSK | Save
  • Phase I study of trifluridine/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors
    Journal Article

    Varghese, A. M.; Cardin, D. B.; Hersch, J.; Benson, A. B.; Hochster, H. S.; Makris, L.; Hamada, K.; Berlin, J. D.; Saltz, L. B.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Outcomes for matched patients with metastatic colitis-associated cancers versus sporadic colorectal cancer receiving chemotherapy
    Meeting Abstract

    Yaeger, R.; Hersch, J.; Bates, D.; Paroder, V.; Chou, J. F.; Tang, L. H.; Gollub, M. J.; Capanu, M.; Kelsen, D. P.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Varghese, A. M.; Backlund Cardin, D.; Hersch, J.; Bowen Benson, A.; Hochster, H. S.; Winkler, R. E.; Benedetti, F.; Hamada, K.; Berlin, J.; Saltz, L. B.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in BRAF V600E colorectal cancer
    Journal Article

    Mondaca, S.; Lacouture, M.; Hersch, J.; Yaeger, R.
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • A phase I dose escalation study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced gastrointestinal (GI) tumors
    Meeting Abstract

    Varghese, A. M.; Cardin, D. B.; Hersch, J.; Benson, A. B.; Hochster, H. S.; Winkler, R.; Benedetti, F.; Hamada, K.; Berlin, J. D.; Saltz, L.
    Cancer Research (2018)

    Fulltext@MSK | Save